{
    "id": 589,
    "fullName": "STK11 wild-type",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "Wild-type STK11 indicates that no mutation has been detected within the STK11 gene.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 6794,
        "geneSymbol": "STK11",
        "terms": [
            "STK11",
            "hLKB1",
            "LKB1",
            "PJS"
        ]
    },
    "variant": "wild-type",
    "createDate": "05/16/2014",
    "updateDate": "08/03/2015",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 1109,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical studies, Glucophage (metformin) inhibited cancer cell growth by activating the AMP kinase pathway in a variety of cancer cell lines that retained one functional allele of STK11 (PMID: 17062558, PMID: 18006825).",
            "molecularProfile": {
                "id": 693,
                "profileName": "STK11 wild-type"
            },
            "therapy": {
                "id": 1031,
                "therapyName": "Metformin",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 853,
                    "pubMedId": 18006825,
                    "title": "Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18006825"
                },
                {
                    "id": 854,
                    "pubMedId": 17062558,
                    "title": "Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17062558"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15163,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, a genomic profile consisted of mutant TP53, wild-type STK11 and EGFR is associated with increased PD-L1 expression and improved progression-free survival in Opdivo (nivolumab)-treated non-small cell lung cancer patients compared to STK11 or EGFR-mutant cohorts (p=0.03) (PMID: 29764856).",
            "molecularProfile": {
                "id": 30811,
                "profileName": "EGFR wild-type STK11 wild-type TP53 mut"
            },
            "therapy": {
                "id": 1312,
                "therapyName": "Nivolumab",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 12766,
                    "pubMedId": 29764856,
                    "title": "TP53, STK11, and EGFR Mutations Predict Tumor Immune Profile and the Response to Anti-PD-1 in Lung Adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29764856"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15162,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, a genomic profile consisted of mutant TP53, wild-type STK11 and EGFR is associated with increased PD-L1 expression and improved progression-free survival in Keytruda (pembrolizumab)-treated non-small cell lung cancer patients (PMID: 29764856).",
            "molecularProfile": {
                "id": 30811,
                "profileName": "EGFR wild-type STK11 wild-type TP53 mut"
            },
            "therapy": {
                "id": 1447,
                "therapyName": "Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 12766,
                    "pubMedId": 29764856,
                    "title": "TP53, STK11, and EGFR Mutations Predict Tumor Immune Profile and the Response to Anti-PD-1 in Lung Adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29764856"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 693,
            "profileName": "STK11 wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 30811,
            "profileName": "EGFR wild-type STK11 wild-type TP53 mut",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}